Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 May 17;143(2):669–680.e12. doi: 10.1016/j.jaci.2018.05.003

Figure 2. R321 inhibits eotaxin/CCR3-mediated chemotaxis.

Figure 2

R321 (0.001–10 μM) dose-response inhibition of chemotaxis induced by CCL11/Eotaxin-1 (12nM), CCL24/Eotaxin-2 (20nM), and CCL26/Eotaxin-3 (100nM) for 4h of (A) blood eosinophils and (B) AML14.3D10-CCR3 cells. (C) IC50/IC90 inhibitory activity of the R321 peptide on eotaxin-induced chemotaxis of blood eosinophils. (D) Scrambled peptide control – R323 (1 μM) does not significantly inhibit chemotaxis of blood eosinophils. In contrast, R321 inhibits chemotaxis by >90% when tested at the same (1 μM) concentration. (E) R321 does not inhibit CXCL12/CXCR4-mediated chemotaxis of Jurkat-T lymphocytic leukemia cells. Results are normalized to % maximum chemotactic response and are representative of the mean ± SEM from experiments (n=3) performed in triplicate. ns=p>0.05.